Checkpoint Therapeutics, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

License Agreements (Details Textual)

License Agreements (Details Textual) - USD ($)	1 Months Ended				2 Months Ended	12 Months Ended
License Agreements (Details Textual) - USD ($)	May 31, 2016	Sep. 30, 2015	May 31, 2015	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2016	Dec. 31, 2015
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Stock Issued During Period, Value, Issued for Services						$ 14,000	$ 1,269,000
Proceeds from Issuance of Common Stock					$ 0	570,000	51,496,000
Neupharma [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Payment Of Upfront Fees				$ 1,000,000
Reimbursement Of Cost Recognized As Revenue						1,000,000
Payment For Non refundable Milestone payments						1,000,000
Neupharma [Member] \| Additional Sales Milestone [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Maximum Potential Milestone Payments						22,500,000
Neupharma [Member] \| Clinical Development Milestone [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Maximum Potential Milestone Payments						40,000,000
Neupharma [Member] \| Regulatory Approvals To Commercialize The Products [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Maximum Potential Milestone Payments						40,000,000
Dana-Farber [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Shares Issued, Price Per Share			$ 0.065
Stock Issued During Period, Shares, Issued for Services		136,830	500,000
Stock Issued During Period, Value, Issued for Services		$ 600,000	$ 32,500
Payment Of Upfront Fees				$ 1,000,000
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners			5.00%
Proceeds from Issuance of Common Stock		$ 10,000,000
Dana-Farber [Member] \| First Commercial Sale Milestone [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue Recognition Milestone Method, Payments Due						21,500,000
Maximum Potential Milestone Payments						21,500,000
Dana-Farber [Member] \| Additional Sales Milestone [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue Recognition Milestone Method, Payments Due						60,000,000
Maximum Potential Milestone Payments						60,000,000
Teva Pharmaceutical Industries Ltd [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Payment Of Upfront Fees						500,000
Teva Pharmaceutical Industries Ltd [Member] \| Clinical Development Milestone [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
License Expense						206,500,000
Teva Pharmaceutical Industries Ltd [Member] \| Regulatory Approvals To Commercialize The Products [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
License Expense						220,000,000
Jubilant Biosys Ltd [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Payments for Other Fees	$ 1,000,000
Payment Of Upfront Fees	2,000,000
Revenue Recognition Milestone Method, Payments Due	$ 87,500,000
Revenue Recognition, Milestone Method, Revenue Recognized						1,500,000
Research and Development Cost, Shared Percentage	50.00%
Jubilant Biosys Ltd [Member] \| Clinical Development Milestone [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Maximum Potential Milestone Payments						89,000,000
Jubilant Biosys Ltd [Member] \| Regulatory Approvals To Commercialize The Products [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
License Expense	$ 59,500,000
Jubilant Biosys Ltd [Member] \| Successful Achievement Of One Preclinical Milestone [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue Recognition Milestone Method, Payments Due	300,000
Jubilant Biosys Ltd [Member] \| Completion Of Three Clinical Development Milestones For Two Licensed Products [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue Recognition Milestone Method, Payments Due	25,500,000
Jubilant Biosys Ltd [Member] \| Five Regulatory Approvals And First Commercial Sales [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Maximum Potential Milestone Payments	61,700,000
Jubilant Biosys Ltd [Member] \| Three Sales Milestones Based On Aggregate Net Sales [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue Recognition Milestone Method, Payments Due	89,000,000
Jubilant Biosys Ltd [Member] \| Sale Millstone [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
License Expense	$ 89,000,000
Collaboration Agreement With TGTX [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue Recognition, Milestone Method, Revenue Recognized						42,000	$ 500,000
Payment Of Upfront Licensing Fee						500,000
Collaboration Agreement With TGTX [Member] \| Clinical Development Milestone [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue Recognition Milestone Method, Payments Due						7,000,000
Collaboration Agreement With TGTX [Member] \| Commercial Sales In Specified Territories [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenue Recognition Milestone Method, Payments Due						$ 14,500,000